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Endovascular technology continues to improve for the treatment of vascular disease. However, application of these
technologies without first obtaining proper informed consent may result in medical malpractice litigation. Similarly, use
of these technologies without proper government and/or hospital approval may result in both criminal and/or civil
liability. Care must be taken when pushing the envelope of endovascular interventions. ( J Vasc Surg 2012;56:273-4.)
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eOff-label use of medical devices is a common practice
among vascular specialists. Should complications arise after
off-label use, and in the event a subsequent medical mal-
practice suit is filed, there is the potential for liability. In
addition, the use of a new device in the hands of an
inexperienced operator can also lead to potential liability.
Use of a US Food and Drug Administration (FDA)-
approved medical device for non-approved indications re-
quires an extensive consent process. Furthermore, off-label
use of a medical device may constitute a regulatory FDA
violation leading to potential civil and criminal liability.
Although many reports in the literature forgivingly refer to
the “learning curve” of any procedure, the legal system is
often not as benevolent concerning complications resulting
from lack of experience with a device or procedure. Before
pushing the endovascular envelope, the vascular specialist
must carefully consider the legal implications if he/she is to
avoid liability.
The definition of off-label use is the use of a medical
device for a purpose other than approved by the FDA.
Specifically, the intended use is not in the cleared “indica-
tions for use.” Use of a device for the purpose for which it
was designed, but not in a manner for which it was ap-
proved, also constitutes off-label use. An example of this
type of off-label use would be the placement of an aortic
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The FDA classifies devices into three basic categories.
lass I consists of devices that are considered to be of
owest risk for harm. These would include elastic bandages
nd examination gloves. Class II devices require labeling
nd performance standards to ensure safety and efficacy and
nclude power wheel chairs and surgical drapes. Class III
evices require clinical studies to ensure safety and efficacy
nd include aortic stent grafts and heart valves.
Once a device has been labeled as class III, the company
roducing the device must make a 510(k) submission to
he FDA, which is a premarket notification to the FDA of
he new device. If there is an equivalent device on the
arket for which premarket approval was not required,
hen it is permissible to market the device. If not, clinical
rials are required. The premarket approval application is
ery stringent and requires significant data that confirm the
fficacy and safety of the device for its intended use.
The primary reason for requiring FDA approval for a
edical device is to prevent inappropriate marketing rather
han inappropriate use of medical devices. In fact, a 1997
mendment to the Food, Drug, and Cosmetic Act stated,
n part, that “Nothing in this Act shall be construed to limit
r interfere with the authority of a health care professional
o prescribe or administer any legally marketed device to a
atient for any condition or disease within a legitimate
ealth practitioner-patient relationship” (SEC. 906 [21
SC sec396] practice of medicine).
In Femrite vs Abbot Northwestern Hospital (568
.W.2d 535), the court concluded that a physician could
se a legally marketed product for any reasonable clinical
ndication. However, this doctrine does not apply if the
ff-label use is in an effort to obtain data to gain FDA
pproval. Further, off-label use is not permitted if the
hysician actively promotes the off-label use. Promotion,
ither by a company or a physician, has been defined as
dvertising the off-label use, dissemination of articles pro-
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July 2012274 Brownmoting the off-label use, physician training which includes
training in off-label use, and reimbursement advice con-
cerning off-label use. Reports concerning off-label use may
be published, but must clearly state that the report consti-
tutes an off-label use of the device. Finally, manufacturers
may not use publications of off-label use to promote further
off-label use of the device.
Off-label use may result in criminal liability, civil liabil-
ity, or both. Criminal liability may occur as a result of
upgrading of services when submitting claims for payment.
This most often occurs through the False Claims Act. To
apply the False Claims Act, the government must show the
existence of three components: (1) a claim was submitted
for payment, (2) a false statement was made, and (3) the
individual knew that it was false. “Knowing” that a claim is
false involves either actual knowledge or complete disre-
gard as to whether the claim is true or false. Penalties for
violating the False Claims Act can be very severe, ranging
from three times the amount of the claim, plus fines of
$5500 to $11,000 per claim. In addition, the government
can file a regulatory action against a physician who know-
ingly causes a device to be shipped in interstate commerce
for a purpose other than its approved use.
Medical malpractice liability may also attach with off-
label use of a medical device. Some courts have suggested
that the off-label use of a medical device constitutes negli-
gence per se, defined as “. . . negligence without any
argument or proof as to the particular surrounding circum-
stances.”1 In cases of negligence per se, no expert is needed
to prove negligence. Rather, it may be assumed by the jury
to have occurred. Another issue often associated with the
off-label use of medical devices is informed consent. An
informed consent note must include at least five basic
components: (1) diagnosis, (2) treatment, (3) risks and
benefits of the planned treatment, (4) other treatment
options, and (5) the natural history of the disease without
treatment. In Estrada vs Jaques (321 S.E.2d 240), a patient
developed a false aneurysm of the superficial femoral artery
as a result of a gunshot wound to the leg. The physicians
involved chose to treat the aneurysmwith coils. The patient
went on to require an amputation. The patient filed suit
alleging that he was not told that the procedure was “ex-
perimental.” The court in this case stated that “. . . the
rewards, financial and professional, attendant upon recog-
nition of experiment success, increase the potential for
abuse and strengthen the rationale for uniform disclosure.”
The court ruled that a physician must exercise reasonable
care and inform a patient of the experimental nature of a
procedure. The physician must also inform the patient not
only of the risks associated with standard treatment, but
also of risks specifically associated with the new procedure.
In this case, the specific risks of the new procedure were not
addressed.
In addition, courts have required that a physician pro-
vide the patient with the physician’s individual experience
and results with the planned procedure. In Johnson vs
Kokemoor (545 N.W.2d 495), the court found that Koke-
moor had not provided informed consent to his patient Secause Dr Kokemoor misrepresented his experience. Last,
f an approved product is to be modified for a specific
rocedure, this must also be carefully and fully explained to
he patient. However, the rule of informed consent does
ot require that the physician inform the patient of the
DA status of the device to be utilized. Specifically, the law
oes not require a vascular surgeon to inform his patient
hat an arterial stent that is to be used in the superficial
emoral artery is FDA-approved only for the biliary system.
n Alvarez vs Smith (714 So.2d 652), the court did state
hat a physician was free to use medical judgment, but
arned that a physician may be held liable for medical
alpractice if that judgment violates the standard of care.
Conflicts, other than those between the physician and
he patient, may arise from the off-label use of a medical
evice. An adversarial relationship may develop between
he physician and the manufacturer. Allegations of a prod-
ct representative promoting off-label use to an unknowing
hysician can occur. There have been cases in which the
anufacturer’s representative suggested a course of action
uring the implantation of a device that resulted in postop-
rative complications. The issue then becomes who is lia-
le, the representative that suggested the treatment, or the
hysician that followed the representative’s advice? To
ate, it has generally been the position of the courts that it
s the physician who must assume the liability.
As noted, representatives are commonly in the operat-
ng room when medical devices are implanted. The Amer-
can College of Surgeons has stated that in cases where a
epresentative is in the operating room, the patient should
e informed of the presence and the purpose of the repre-
entative, and give acknowledgment in writing that he/she
as been so notified.2 If this consent is not obtained, the
hysician, the representative, and the parent device com-
any could all potentially be liable for invasion of privacy
nd/or intentional infliction of emotional distress.
In conclusion, off-label use of a medical device should
onform to the standard of care. Before off-label use, a
hysician should be able to demonstrate both familiarity
nd skill with the device in question. Large-scale off-label
se of a device to promote a physician’s practice or to
xpand the indications for a device should be avoided.
ppropriately informed consent must be obtained before
ny off-label use of a medical device. Consent should
ontain an explanation of the risks and benefits of both the
tandard treatment and the planned off-label use. Care
hould be taken in submitting billing for the off-label use of
edical devices if liability for False Claims Act violation is to
e avoided.
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